|Bid||18.13 x 900|
|Ask||18.15 x 800|
|Day's Range||17.82 - 18.25|
|52 Week Range||11.46 - 24.30|
|Beta (3Y Monthly)||4.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.89|
HENDERSON, NV / ACCESSWIRE / November 21, 2018 / Moderna and Synthorx's huge IPOs show biotech point to a strong biotech sector that should continue a bull run heading into the new year. CBD based biotechs ...
MedMen (MMNFF) has entered into agreements with different companies to expand its footprint. We outline a few of the recent agreements below.
Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary in the Midtown area. The above chart lists the details about Curaleaf’s new dispensary in Tallahassee.
For investors who are seeking exposure to the cannabis industry but consider pure-play companies too risky, there are many other interesting investment opportunities. Pharma and biotech companies have ...
Corbus Pharmaceuticals Holdings (CRBP) is a clinical-stage pharmaceutical company focused on developing and commercializing products for rare, life-threatening inflammatory fibrotic diseases.
22nd Century Group (XXII) is a plant biotechnology company that’s focused on developing technologies to manage the nicotine content in tobacco plants and the cannabinoids in cannabis plants using gene editing and plant breeding technologies.
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Cara Therapeutics (CARA) is a clinical-stage biotechnology company developing new chemical entities for managing pain and pruritus. Cara Therapeutics reported EPS of -$0.52 on revenue of $2.87 million in the second quarter.
Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.
STAMFORD, Conn., Nov. 08, 2018 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.
Cara (CARA) delivered earnings and revenue surprises of -10.87% and 7.34%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Stamford, Connecticut-based company said it had a loss of 51 cents. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Nov. 06, 2018 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing.
HENDERSON, NV / ACCESSWIRE / November 1, 2018 / A stem cell play we like a lot is BioRestorative Therapies, Inc.,(BRTX) a life sciences company focused on stem cell-based therapies. Defined Health is a business development and strategy consulting firm that has worked with many of the leading companies in the pharmaceutical, biotech and healthcare industries for over 25 years. BRTX plans to use the results of the review to further refine its planned activities around BRTX-100, including potential licensing, co-development and commercialization activities.
STAMFORD, Conn., Oct. 30, 2018 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.
Which stock wins in a matchup between a high-flying clinical-stage biotech and a leading supplier to the marijuana industry?
Broadly the industry is divided into two markets: the market for medical marijuana and the one for recreational marijuana. According to a report released by research firm ArcView Market Research and BDS analytics, the overall share of the medical marijuana industry slid from 100% in 2013 to 71% in 2017. As of this writing, nine states have completely legalized recreational marijuana.) By 2027, medical marijuana will be just 33% of the overall market states ArcView.
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today announced the appointment of Joana Goncalves, M.D., as Chief Medical Officer (CMO). “We are very pleased to welcome Joana to the Cara team.
Marijuana stocks, fueled by what may well be the biggest legal and medical revolution in years, have already proven they’re blazing their own trail. In all cases, though, there’s explosive potential on the table — the legal marijuana industry’s story has just gotten that compelling, as more states seek to legalize it while regulators finally start to see its legitimate medical benefits. Of all the marijuana stocks worth a look right now, Canopy Growth (NYSE:CGC) has garnered the most attention of late.
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Insys Therapeutics (INSY) is a specialty pharmaceuticals company focused on developing cannabinoids and sprays. It reported EPS of -$0.37 on revenues of $23.47 million in the second quarter of 2018.